SARS-CoV2 in patients on antiviral HBV and HCV therapy in Spain
The impact of SARS-CoV2 in patients with underlying chronic liver disease is still a matter of analysis within the Hepatology community1. We read with great interest several studies suggesting that antivirals against HCV or HBV could be evaluated as COVID-19 therapeutics. A study virtually screening usable therapeutics against SARS-CoV-2 showed that inhibitors of the NS5A protein of the hepatitis C virus (HCV) velpatasvir and ledipasvir were among the 16 candidates which gave promising binding models2.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Sabela Lens, Mireia Miquel, Beatriz Mateos-Mu ñoz, Javier García-Samaniego, Xavier Forns Tags: Letter to the Editor Source Type: research
More News: COVID-19 | Gastroenterology | Hepatitis | Hepatitis C | Liver | Liver Disease | SARS | Spain Health | Study | Urology & Nephrology